购物车 
-
利巴韦林
NMR and HPLC COA下载 MSDS下载 - Names：
Ribavirin, Antiviral nucleoside
- CAS号：
36791-04-5
MDL Number： MFCD00058564 - MF(分子式)： C8H12N4O5 MW(分子量)： 244.2
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
利巴韦林(Ribavirin,36791-04-5)是一种1-核糖基三唑，它是1,2,4-三唑-3-羧酰胺的1-核呋喃糖基衍生物。 合成的鸟苷类似物，是HCV聚合酶的抑制剂，对DNA和RNA病毒具有广泛的活性。 利巴韦林具有抗代谢药，抗病毒药，抗感染药，EC 2.7.7.49（RNA定向DNA聚合酶）抑制剂和抗冠状病毒制剂的作用。 利巴韦林是1-核糖基三唑，芳族酰胺和一元羧酸酰胺。
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000551-200mg | 200mg | 99.8% | ¥ 896.00 | ¥ 896.00 | 2-3天 | ¥ 0.00 | ||
| YZM000551-100mg | 100mg | 99.8% | ¥ 520.00 | ¥ 520.00 | 2-3天 | ¥ 0.00 | ||
| SS0312-25g | 25g | 99% | ¥ 170.67 | ¥ 170.67 | 126 | Instock,1days | ¥ 0.00 | |
| SS0312-100g | 100g | 99% | ¥ 580.00 | ¥ 580.00 | 433 | Instock 1days | ¥ 0.00 | |
| SS0312-500g | 500g | 99% | ¥ 1300.00 | ¥ 1300.00 | 964 | Instock 1days | ¥ 0.00 | |
| SS0312-5g | 5g | 99% | ¥ 68.00 | ¥ 68.00 | 48 | Instock,1days | ¥ 0.00 |
| 中文别名 | 利巴韦林(cas:36791-04-5);1-beta-D-呋喃核糖基-1H-1,2,4,-三氮唑-3-羧酰胺; 利巴韦林; 1-B-D呋喃核糖-1,2,4-三氮唑-3-羟酰胺; 病毒唑; 三氮唑核苷; 1-β-D-呋喃核糖-1,2,4-三氮唑-3-羟酰胺; 三氨唑核苷; 1-Β-D-呋喃核糖苷-1H-1,2,4-三氮唑-3-羧酰胺; 三唑核苷; 酰胺三嗪核苷 |
| 英文别名 | Ribavirin, Antiviral nucleoside(cas:36791-04-5),ribavirin, Ribasphere, Ribavirine, Ribavirina, Ribavirinum |
| CAS号 | 36791-04-5 |
| Inchi | InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1 |
| InchiKey | IWUCXVSUMQZMFG-AFCXAGJDSA-N |
| 分子式 Molecular Weight | C8H12N4O5 |
| 分子量 Formula | 244.2 |
| 溶解度Solubility | H2O≥ 83.3 mg/mL(341.11 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性状 | 固体粉末,Power |
| 储藏条件 Storage conditions | -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
Ribavirin(CAS:36791-04-5)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:利巴韦林蒸汽压,利巴韦林合成,利巴韦林标准,利巴韦林应用,利巴韦林合成,利巴韦林沸点,利巴韦林闪点,利巴韦林用途,利巴韦林溶解度,利巴韦林价格,利巴韦林作用,利巴韦林结构式,利巴韦林用处,利巴韦林毒理性质
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:利巴韦林蒸汽压,利巴韦林合成,利巴韦林标准,利巴韦林应用,利巴韦林合成,利巴韦林沸点,利巴韦林闪点,利巴韦林用途,利巴韦林溶解度,利巴韦林价格,利巴韦林作用,利巴韦林结构式,利巴韦林用处,利巴韦林毒理性质
| 产品说明 | 利巴韦林(36791-04-5,Ribavirin) (ICN-1229) 是广谱的抗病毒药，可抑制HCV，HIVl，RSV等病毒 |
| Introduction | Ribavirin(利巴韦林,36791-04-5) (ICN229) is anantiviralagent against a broad spectrum of viruses includingHCV,HIVl, andRSV. |
| Application1 | |
| Application2 | |
| Application3 |
Ribavirin description:
1.Ribavirin is a 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. A synthetic guanosine analogue, it is an inhibitor of HCV polymerase and possesses a broad spectrum of activity against DNA and RNA viruses. It has a role as an antimetabolite, an antiviral agent, an antiinfective agent, an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor and an anticoronaviral agent. It is a 1-ribosyltriazole, an aromatic amide and a monocarboxylic acid amide.
2.Ribavirin is a nucleoside analogue and antiviral agent used in therapy of chronic hepatitis C and other flavivirus infections. Ribavirin has not been associated with clinically apparent liver injury.
3.Ribavirin is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.
1.Ribavirin is a 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. A synthetic guanosine analogue, it is an inhibitor of HCV polymerase and possesses a broad spectrum of activity against DNA and RNA viruses. It has a role as an antimetabolite, an antiviral agent, an antiinfective agent, an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor and an anticoronaviral agent. It is a 1-ribosyltriazole, an aromatic amide and a monocarboxylic acid amide.
2.Ribavirin is a nucleoside analogue and antiviral agent used in therapy of chronic hepatitis C and other flavivirus infections. Ribavirin has not been associated with clinically apparent liver injury.
3.Ribavirin is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.
| 警示图 | |
| 危险性 | warning |
| 危险性警示 | Not available |
| 安全声明 | H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害 |
| 安全防护 | P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理 |
| 备注 | 实验过程中防止吸入、食入，做好安全防护 |
| Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) U |
| Potential benefits of combination of Nigella sativa and Zn supplements to treat COVID-19 Journal of herbal medicine 2020-10-01 |
| Ribavirin therapy for severe COVID-19: a retrospective cohort study International journal of antimicrobial agents 2020-09-01 |
| Clinical Trials of Repurposed Antivirals for SARS-CoV-2 Antimicrobial agents and chemotherapy 2020-08-20 |
| Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic Alternative therapies in health and medicine 2020-08-20 |
1.Retreatment of Hepatitis C with Consensus Interferon and Ribavirin After Nonresponse or Relapse to Pegylated Interferon and Ribavirin: A National VA Clinical Practice Study Digestive Diseases and Sciences 2011
Abstract:
(1)Background:Studies of the retreatment with consensus interferon (CIFN) and ribavirin (RBV) of hepatitis C virus (HCV)-infected patients who failed prior pegylated interferon alfa/ribavirin (PEG-IFN/RBV) have found quite variable efficacy and tolerability of this therapy . As such, CIFN/RBV use and efficacy in clinical practice were evaluated within the Department of Veterans Affairs (VA), the largest national, integrated system for HCV care.
(2)Aims:The purpose of this study was to determine rates of sustained virologic response (SVR) and patterns of CIFN/RBV use in the VA. Methods included retrospective review of national VA data in HCV-infected patients who had previously failed ≥12 weeks of PEG- IFN/RBV and were prescribed CIFN/RBV between October 1, 2003 and September 30, 2006.
(3)Results:A total of 597 patients met the study criteria. CIFN was primarily dosed as 15 mcg subcutaneously daily combined with standard doses of RBV. Mean treatment duration was 21 weeks; CIFN was discontinued within 4 weeks in 24%. Hematological growth factors were used in 49 %. Post-treatment viral loads were available in 385 patients. SVR to CIFN/RBV was achieved in 11%, and was significantly higher in prior PEG-IFN/RBV relapsers compared with nonresponders (31% vs. 6%, respectively; P <0.0001). A 2-log10 or greater drop in HCV RNA after 24 weeks of PEG-IFN/RBV was a predictor of subsequent SVR to CIFN/RBV.
(4)Conclusions:CIFN/RBV was used frequently in clinical practice for retreatment of PEG-IFN/RBV. In this setting, early treatment discontinuation was common. Overall SVR was low, although response was significantly better in prior PEG-IFN/RBV relapsers and those who had a 2-log10 or greater decline than in nonresponders.
2.Blood cell, liver function, and response changes by PEG-interferon-α2b plus ribavirin with polaprezinc therapy in patients with chronic hepatitis C Hepatology International 2008
Abstract:
(1)Purpose:Zinc has been reported to ameliorate hematologic side effects and improve liver function. In addition to its various effects, zinc supplementation in chronic hepatitis C patients with genotype 1b of high viral load enhanced the response to interferon (IFN) monotherapy. This study was aimed at clarifying whether zinc could improve hematologic side effects, improve liver function, and enhance the response to therapy in patients with chronic hepatitis C treated with pegylated-interferon (PEG-IFN) plus ribavirin (RBV).
(2)Methods:The 32 patients enrolled in the study were randomly divided into two groups: a PEG-IFN-α2b plus RBV with zinc group (PEG/RBV + zinc, n = 16) and a PEG-IFN-α2b plus RBV group (PEG/RBV, n = 16). HCV-RNA, serum zinc, ALT, white blood cell, red blood cell, platelet, and hemoglobin (Hb) levels were examined.
(3)Results:Serum zinc levels were significantly higher in the PEG/RBV with zinc group than in the PEG/RBV without zinc group at 4, 8, and 12 weeks. No significant differences were observed in the clearance of HCV-RNA between the two groups. The outcome of the treatment was similar; results of laboratory examinations including ALT before, during, and after therapy revealed no significant differences between the two groups at any point in all items except serum zinc levels. A sustained virological response rate was observed in 50.0% in the PEG/RBV with zinc group and 43.8% in the PEG/RBV without zinc group, with no significant difference between the two groups.
(4)Conclusions:The study demonstrated no evidence that zinc ameliorates hematologic side effects, improves liver function, and enhances the response to the therapy in chronic hepatitis C receiving PEG-IFN-α2b plus RBV.
Abstract:
(1)Background:Studies of the retreatment with consensus interferon (CIFN) and ribavirin (RBV) of hepatitis C virus (HCV)-infected patients who failed prior pegylated interferon alfa/ribavirin (PEG-IFN/RBV) have found quite variable efficacy and tolerability of this therapy . As such, CIFN/RBV use and efficacy in clinical practice were evaluated within the Department of Veterans Affairs (VA), the largest national, integrated system for HCV care.
(2)Aims:The purpose of this study was to determine rates of sustained virologic response (SVR) and patterns of CIFN/RBV use in the VA. Methods included retrospective review of national VA data in HCV-infected patients who had previously failed ≥12 weeks of PEG- IFN/RBV and were prescribed CIFN/RBV between October 1, 2003 and September 30, 2006.
(3)Results:A total of 597 patients met the study criteria. CIFN was primarily dosed as 15 mcg subcutaneously daily combined with standard doses of RBV. Mean treatment duration was 21 weeks; CIFN was discontinued within 4 weeks in 24%. Hematological growth factors were used in 49 %. Post-treatment viral loads were available in 385 patients. SVR to CIFN/RBV was achieved in 11%, and was significantly higher in prior PEG-IFN/RBV relapsers compared with nonresponders (31% vs. 6%, respectively; P <0.0001). A 2-log10 or greater drop in HCV RNA after 24 weeks of PEG-IFN/RBV was a predictor of subsequent SVR to CIFN/RBV.
(4)Conclusions:CIFN/RBV was used frequently in clinical practice for retreatment of PEG-IFN/RBV. In this setting, early treatment discontinuation was common. Overall SVR was low, although response was significantly better in prior PEG-IFN/RBV relapsers and those who had a 2-log10 or greater decline than in nonresponders.
2.Blood cell, liver function, and response changes by PEG-interferon-α2b plus ribavirin with polaprezinc therapy in patients with chronic hepatitis C Hepatology International 2008
Abstract:
(1)Purpose:Zinc has been reported to ameliorate hematologic side effects and improve liver function. In addition to its various effects, zinc supplementation in chronic hepatitis C patients with genotype 1b of high viral load enhanced the response to interferon (IFN) monotherapy. This study was aimed at clarifying whether zinc could improve hematologic side effects, improve liver function, and enhance the response to therapy in patients with chronic hepatitis C treated with pegylated-interferon (PEG-IFN) plus ribavirin (RBV).
(2)Methods:The 32 patients enrolled in the study were randomly divided into two groups: a PEG-IFN-α2b plus RBV with zinc group (PEG/RBV + zinc, n = 16) and a PEG-IFN-α2b plus RBV group (PEG/RBV, n = 16). HCV-RNA, serum zinc, ALT, white blood cell, red blood cell, platelet, and hemoglobin (Hb) levels were examined.
(3)Results:Serum zinc levels were significantly higher in the PEG/RBV with zinc group than in the PEG/RBV without zinc group at 4, 8, and 12 weeks. No significant differences were observed in the clearance of HCV-RNA between the two groups. The outcome of the treatment was similar; results of laboratory examinations including ALT before, during, and after therapy revealed no significant differences between the two groups at any point in all items except serum zinc levels. A sustained virological response rate was observed in 50.0% in the PEG/RBV with zinc group and 43.8% in the PEG/RBV without zinc group, with no significant difference between the two groups.
(4)Conclusions:The study demonstrated no evidence that zinc ameliorates hematologic side effects, improves liver function, and enhances the response to the therapy in chronic hepatitis C receiving PEG-IFN-α2b plus RBV.
对不起，暂无产品评价！
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
怎么做细胞爬片免疫组化染色实验
细胞爬片免疫组化染色，是通过细胞爬片是让玻片浸在细胞培养基内，细胞在玻片上生长，主要用于组织学，免疫组织化学...
2020/7/20 22:04:33
提取病毒RNA的实验方法
提取病毒RNA方法分别有：异硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
chelex 100树脂国产替代之路-BIOFOUNT范德生物
Chelex 100螯合离子交换树脂对铜、铁和其他重金属?的偏好显著高于对钠、钾等一价阳离子的偏好。它对二价...
2025/11/4 14:22:46
9月开学季——助研新学期 范德送好礼
2025/8/28 15:30:55
Waxfilm 实验室封口膜：技术与国际市场的双重突破
在实验室耗材领域，封口膜是保障实验准确性与稳定性的关键产品之一。近年来，Waxfilm?实验室封口膜凭借其卓...
2025/5/13 13:03:40
Waxfilm实验室封口膜的5大突破
Waxfilm实验室封口膜作为生物功能膜领域的国产技术突破和品牌突破，是生物领域中国技术发展的缩影。
2025/5/6 17:02:07
各种微流控芯片键合方法的优缺点
微流控芯片键合：目前主要有激光焊接、热压键合、胶键合、超音波焊接，每种方法都有各自的优缺点。本文主要介绍聚酯...
2023/7/28 10:43:09
新一代微流控键合解决方案
微流控键合解决方案：微流控芯片制造的一个重要环节，也是最容易被忽视的--芯片键合。其中一个重要因素是：微流控...
2023/7/27 12:44:28
荧光素钾盐使用说明
D-荧光素钾盐（K+）设计用于体外和体内生物发光测定。D-荧光素的质量和纯度对于获得良好和可重复的结果至关重...
2023/7/20 11:05:11
如何选BSA（牛血清白蛋白）
如何选BSA（牛血清白蛋白）：牛血清白蛋白（BSA）有多种形式，如何选择适合自己的牛血清白蛋白（BSA）是一...
2023/2/14 13:09:18
